An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Clinical trial NCT02565186 · COMPLETED

Trial details

NCT number: NCT02565186
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Migraine Disorders

Start date: 2015-10-07
Primary completion: 2019-08-20
Enrollment: 2171

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.